Epidemiological profile analysis and incidence of yellow fever in Brazil

Anne Francielle Santos Calado, Francisco Adalberto do Nascimento Paz

Abstract


Yellow fever is an arbovirus produced by a Flavivirus, family Flaviviridae. The disease is endemic and enzootic in several tropical regions of the Americas and Africa. Objective: To describe the epidemiological profile of reported cases of yellow fever in the Brazilian population between 2010 and 2019 from a careful analysis of data obtained from the epidemiological databases of the Ministry of Health. Data analysis of the Brazilian Health System was performed. Reporting Disease Information (SINAN), and epidemiological data reported by the Ministry of Health, the variables evaluated were: country regions, age group, gender, disease evolution, in timeframe from 2010 to 2019. The incidence of cases yellow fever in Brazil, according to epidemiological records notified by the Ministry of Health, pointed to a high upward trend from 2016 to 2018, with higher incidence rates in the Southeast and Midwest regions, although there was a significant increase in notifications in other regions of the country. Statistically significant differences were found between genders, being the male sex most affected by the disease, and in relation to the age group most affected, we identified the young population between 20-59 years. Therefore, yellow fever presented itself as an important public health problem in the country, with active transmission and persistence of foci of transmission, requiring greater attention to this disease and its alarming risks. It is important to highlight the relevance of vaccines, and medicines that can fight the virus.


Keywords


Yellow fever; Epidemiology; Public health; Health information system; Time series study.

References


Brasil, MS (2009). Febre Amarela (Caderno 9). Guia de Vigilância Epidemiológica. Brasília: Ministério da Saúde; 816. Britol, BM et al (2014). Febre amarela: Uma revisão de literatura. Brazilian Journal of Surgery and Clinical Research, BJSCR,8(3):61-65.

Cavalcante, KRLJ; Tauil, PL (2016). Epidemiological characteristics of yellow fever in Brazil, 2000-2012. Epidemiol. Serv. Saúde, Brasília, 25(1).

Costa, ZGA; Oliveira, RC; Tuboi, SH; Silva, MM & Vasconcelos, PFC (2002). Redefinição das áreas de risco para febre amarela silvestre no Brasil. Revista da Sociedade Brasileira de Medicina Tropical 35: 84.

Freire, FD; Gomes, CHM; Cardoso, PS & Moura, AS (2018). Febre amarela: uma velha doença, mas com novos desafios. ConexCienc; 13(1): 79-86.

Jenningsa, D; Gibson, CA; Millerb, R; Matthews, JH; Mitchell, CJ; Roehrig, JT; Woodd, J; Taffs, F; Sil, BK; Whitby, SN; Minord; Monath, T & Barrett, ADT (1994). Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. Journal of Infectious Diseases 169:512-518.

Linthicum, KJ; Bailey, CL; Davies, FG & Tucker, CJ (1987). Detection of Rift Valley fever viral activity in Kenya by satellite remotesens in gimagery. Science. 235(4796): 1656.

Noronha, TG; Camacho, LAB (2017). Controversies in the expansion of are as with routine yellow fever vaccination in Brazil. Cad. Saúde Pública; 33(10): 00060917.

Pan american health organization (2002). Casos y muertes por fiebre amarilla en región de las Américas. Pan American Health Organization, Washington, 25.

Pereira, A.S. et al. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed.UAB/NTE/UFSM. Disponível em: https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1. Acesso em: 04.12. 2019.

Romano, APM; Ramos, DG; Araújo FA; Siqueira, G; Ribeiro, MP; Leal & SG et al. (2011). Febre amarela no Brasil: recomendações para a vigilância, prevenção e controle. Epidemiol e Serviços Saúde, (12),5.

Romano, AP; Costa, ZG; Ramos, DG; Andrade, MA; Jaume, V & Almeida, MA et al (2014).Yellow fever out breaks in um vaccinated populations, Brazil, 2008-2009. PloS Negl Trop Dis; 8(3): 18-21.

Robertsonse (1993). The immunological basis for immunization series: Yellow fever. World Health Organization, Geneva, 25.

Sacramento, CQ (2017).The clinically approved antiviral drugs of sofusbovir irinhibits Zika virus replication. Sci Rep, (7): 40920.

Saúde, M (2017). Febre Amarela. Profissionais de Saúde: Informações para profissionais. (27) |2017/2018.




DOI: http://dx.doi.org/10.33448/rsd-v9i3.2271

Refbacks

  • There are currently no refbacks.


Base de Dados e Indexadores: Base, Diadorim, Sumarios.org, DOI Crossref, Dialnet, Scholar Google, Redib, Doaj, Latindex, Portal de Periódicos CAPES

Research, Society and Development - ISSN 2525-3409

Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional

Rua Irmã Ivone Drumond, 200 - Distrito Industrial II, Itabira - MG, 35903-087 (Brasil) 
E-mail: rsd.articles@gmail.com